Arkansas Patent of the Month – August 2024
In the fight against bacterial infections, BioVentures, LLC has developed a novel approach to non-invasively detect and treat harmful pathogens in the bloodstream. With antibiotic resistance on the rise, BioVentures’ novel method offers a promising alternative to traditional antimicrobial treatments, which often struggle to keep up with rapidly evolving bacteria. The method centers on an advanced laser-based technology that integrates both diagnostic and therapeutic functions, opening new avenues for targeted medical interventions.
The core of BioVentures’ innovation lies in integrated photoacoustic and photothermal nano-theranostics. This technique utilizes laser pulses to illuminate and analyze circulating target objects in the blood, lymph, and other vessels, such as bacteria, cancer cells, and even drug-resistant pathogens. The process begins with low-energy diagnostic laser pulses, which interact with the target objects to emit specific signals. These signals, including photoacoustic and photothermal responses, are then detected using ultrasound transducers or photodiodes, allowing for precise identification of the targets.
Once the targets are identified, a high-energy therapeutic laser pulse is deployed to generate photothermal nanobubbles that selectively destroy the harmful cells without affecting the surrounding healthy tissue. This method offers the unique ability to treat conditions like bacterial infections, metastasis, thrombosis, and more without relying on antibiotics. It also provides real-time monitoring capabilities, ensuring the treatment’s effectiveness by adjusting to the frequency and characteristics of the detected signals.
BioVentures’ approach is particularly effective against **antibiotic-resistant strains** such as MRSA, which pose significant challenges to healthcare systems worldwide. By bypassing traditional drug pathways, this method can eliminate these pathogens regardless of their resistance status, offering a significant advantage over conventional treatments.
The technology is versatile, applicable to a wide range of organisms and conditions, from viral infections to cancer metastasis. Its ability to identify and quantify circulating targets, like cancer cells and pathogens, offers valuable diagnostic insights and immediate therapeutic action, making it a powerful tool for precision medicine.
BioVentures’ pioneering work in photoacoustic and photothermal therapy is poised to revolutionize how we approach disease management. As research continues, this technology holds the potential to become a cornerstone in the next generation of medical treatments, providing safer, more efficient solutions for patients worldwide. With its focus on non-invasive, label-free, and highly selective treatment methods, BioVentures is setting a new standard in medical innovation.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
